Amino-terminally truncated MCP-2 as chemokine antagonists
View Patent ↗The present invention relates to amino-terminally truncated MCP-2, lacking NH 2 -terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
1. An isolated amino-terminally truncated MCP-2 polypeptide consisting of residues 2-76 of SEQ ID NO:1, wherein the truncated MCP-2 polypeptide lacks NH 2 -terminal amino acid residue 1 of SEQ ID NO:1 and has chemokine antagonistic activity.
2. The isolated amino-terminally truncated MCP-2 polypeptide of claim 1 , wherein the truncated MCP-2 polypeptide is in glycosylated form.
3. A pharmaceutical composition comprising an isolated truncated MCP-2 polypeptide according to claim 1 , wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.
4. The pharmaceutical composition according to claim 3 , wherein the isolated truncated MCP-2 polypeptide is in glycosylated form.
5. An isolated amino-terminally truncated MCP-2 polypeptide consisting of residues 3-76 of SEQ ID NO:1, wherein the truncated MCP-2 polypeptide lacks NH 2 -terminal amino acid residues 1-2 of SEQ ID NO:1 and has chemokine antagonistic activity.
6. The isolated amino-terminally truncated MCP-2 polypeptide of claim 5 , wherein the truncated MCP-2 polypeptide is in glycosylated form.
7. A pharmaceutical composition comprising an isolated truncated MCP-2 polypeptide according to claim 5 , wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.
8. The pharmaceutical composition according to claim 7 , wherein the isolated truncated MCP-2 polypeptide is in glycosylated form.
9. An isolated amino-terminally truncated MCP-2 polypeptide consisting of residues 4-76 of SEQ ID NO:1, wherein the truncated MCP-2 polypeptide lacks NH2-terminal amino acid residues 1-3 of SEQ ID NO:1 and has chemokine antagonistic activity.
10. The isolated amino-terminally truncated MCP-2 polypeptide of claim 9 , wherein the truncated MCP-2 polypeptide is in glycosylated form.
11. A pharmaceutical composition comprising an isolated truncated MCP-2 polypeptide according to claim 9 , wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.
12. The pharmaceutical composition according to claim 11 , wherein the isolated truncated MCP-2 polypeptide is in glycosylated form.
13. An isolated amino-terminally truncated MCP-2 polypeptide consisting of residues 5-76 of SEQ ID NO:1, wherein the truncated MCP-2 polypeptide lacks NH 2 -terminal amino acid residues 1-4 of SEQ ID NO:1 and has chemokine antagonistic activity.
14. The isolated amino-terminally truncated MCP-2 polypeptide of claim 13 , wherein the truncated MCP-2 polypeptide is in glycosylated form.
15. A pharmaceutical composition comprising an isolated truncated MCP-2 polypeptide according to claim 13 , wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.
16. The pharmaceutical composition according to claim 15 , wherein the isolated truncated MCP-2 polypeptide is in glycosylated form.
17. An isolated amino-terminally truncated MCP-2 polypeptide consisting of residues 6-76 of SEQ ID NO:1, wherein the truncated MCP-2 polypeptide lacks NH 2 -terminal amino acid residues 1-5 of SEQ ID NO:1 and has chemokine antagonistic activity.
18. The isolated amino-terminally truncated MCP-2 polypeptide of claim 17 , wherein the truncated MCP-2 polypeptide is in glycosylated form.
19. A pharmaceutical composition comprising an isolated truncated MCP-2 polypeptide according to claim 17 , wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.
20. The pharmaceutical composition according to claim 19 , wherein the isolated truncated MCP-2 polypeptide is in glycosylated form.